{"id":942728,"date":"2026-03-06T16:08:28","date_gmt":"2026-03-06T21:08:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"},"modified":"2026-03-06T16:08:28","modified_gmt":"2026-03-06T21:08:28","slug":"absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","title":{"rendered":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">VANCOUVER, Wash. and NEW YORK, March  06, 2026  (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci\u2019s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci\u2019s Board of Directors pursuant to Absci\u2019s 2023 Inducement Plan (the \u201cInducement Plan\u201d), and is being made as an inducement material to the new employee\u2019s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">The stock option award has an exercise price of $2.57 per share, the closing price of Absci\u2019s common stock on the Nasdaq Global Select Market on March 3, 2026 (the \u201cGrant Date\u201d). The stock option award has a 10-year term and vests over four years, with 25% of the shares subject to the option vesting and exercisable on the one-year anniversary of the Grant Date while the remaining 75% of the shares vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to Dr. Somaratne will be fully vested on the fourth anniversary of the Grant Date, subject to Dr. Somaratne\u2019s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).<\/p>\n<p align=\"justify\">\n        <strong>About Absci<\/strong>\n      <\/p>\n<p align=\"justify\">Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci\u2019s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201\u2122, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential \u201cbest-in-class\u201d therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xk0BxJeTLUCHFtgst7mSmyafR1VS8RaODQDherucfs4x0L1tib9k9xZh--Z97orb_rl0GQ0E2ZUVjoTqjkJ-Cw==\" rel=\"nofollow\" target=\"_blank\"><u>www.absci.com<\/u><\/a> or follow us on LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ecxr14NES-vDVhFCnwZS9o5Y-1U1N7AoUUG9X9Koq3AOj4RqdPreeHLo4eWH15MrFXaZHYg7sYWZicCzVv8HFC0gBXBglzWuxC5pcITNfKQ=\" rel=\"nofollow\" target=\"_blank\"><u>@absci<\/u><\/a>), X (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j-Git91i0ga3MPCazuKwSJP1chgEa2km7k0EzxjvYxMJd3tpBi9gnoDJnMpXLx0jbjjDAc6OzwQJKd8pjZUVHA==\" rel=\"nofollow\" target=\"_blank\"><u>@Abscibio<\/u><\/a>) and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GOj2AlqG1l-AO0fCdbIAvJzr4EnYMeeRv0g1Bm_1VkYa0YJMa8-jRiVUE3Wpe0AQ6pcIzQmtmD065WTp9MlgLIw5mkJZnIDhCXsS8weiGLg=\" rel=\"nofollow\" target=\"_blank\"><u>YouTube<\/u><\/a>.<\/p>\n<p align=\"justify\">Absci<sup>\u00ae<\/sup> standard character mark, ABS-201\u2122, and Integrated Drug Creation\u2122 are trademarks and registered trademarks of Absci Corporation.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Alexander D.H. Khan<br \/>Corporate Vice President<br \/>Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M7GP7jGOHl1hc6icADoRIVf2rqnmdcrayiTWp5ycB-v3SN2hDJ2qoPAmAPwKxb0Aq6C94iDRm37B3LPu2jbz812kOljy3qn-ci8qkoCTfpI=\" rel=\"nofollow\" target=\"_blank\">investors@absci.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P3usk_r1Z2hMynkXeioDAZxresjMKpTezoIQSnwRwGe_xuSlPd-5NazhvRsDcInsGJbrupt2nelgCXqohUDLcA==\" rel=\"nofollow\" target=\"_blank\">press@absci.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjgyNzRiM2ItYzk3MS00MzIwLTgyMjMtNWU1OTdkMTM1YjlkLTEyMjE2MzMtMjAyNi0wMy0wNi1lbg==\/tiny\/ABSCI-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci\u2019s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci\u2019s Board of Directors pursuant to Absci\u2019s 2023 Inducement Plan (the \u201cInducement Plan\u201d), and is being made as an inducement material to the new employee\u2019s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option award has an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942728","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci\u2019s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci\u2019s Board of Directors pursuant to Absci\u2019s 2023 Inducement Plan (the \u201cInducement Plan\u201d), and is being made as an inducement material to the new employee\u2019s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option award has an &hellip; Continue reading &quot;Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-06T21:08:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-03-06T21:08:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\"},\"wordCount\":478,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\",\"name\":\"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=\",\"datePublished\":\"2026-03-06T21:08:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","og_locale":"en_US","og_type":"article","og_title":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) &#8212; Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci\u2019s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci\u2019s Board of Directors pursuant to Absci\u2019s 2023 Inducement Plan (the \u201cInducement Plan\u201d), and is being made as an inducement material to the new employee\u2019s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option award has an &hellip; Continue reading \"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-06T21:08:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-03-06T21:08:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"},"wordCount":478,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/","name":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=","datePublished":"2026-03-06T21:08:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2Njc0MiM3NDcwMTU3IzIyMTAwODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942728"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942728\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}